Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
- Division of Nuclear Medicine, Department of Radiology, Mayo Clinic Rochester, Minneapolis, 55905, United States; OSTI
- Division of Nuclear Medicine, Department of Radiology, Mayo Clinic Rochester, Minneapolis, 55905, United States
The present review describes the methodological aspects and prospects of the productionof Positron Emission Tomography (PET) radiometals in a liquid target using low-medium energymedical cyclotrons. The main objective of this review is to delineate and discuss the critical factorsinvolved in the liquid target production of radiometals, including type of salt solution, solutioncomposition, beam energy, beam current, the effect of irradiation duration (length of irradiation)and challenges posed by in-target chemistry in relation with irradiation parameters. We also summarizethe optimal parameters for the production of various radiometals in liquid targets.
:Additionally, we discuss the future prospects of PET radiometals production in the liquid targetsfor academic research and clinical applications. Significant emphasis has been given to the productionof68Ga using liquid targets due to the growing demand for68Ga labeled PSMA vectors, [68Ga]-Ga-DOTATATE, [68Ga]Ga-DOTANOC and some upcoming68Ga labeled radiopharmaceuticals.Other PET radiometals included in the discussion are86Y,63Zn and89Zr.
- Research Organization:
- Mayo Clinic, Rochester, MN (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC)
- DOE Contract Number:
- SC0008947;
- OSTI ID:
- 1851172
- Journal Information:
- Current Radiopharmaceuticals, Journal Name: Current Radiopharmaceuticals Journal Issue: 4 Vol. 14; ISSN 1874-4710
- Publisher:
- Bentham Science Publishers
- Country of Publication:
- United States
- Language:
- English
Similar Records
{sup 68}Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement
Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]